Tags

Type your tag names separated by a space and hit enter

The new ACR/EULAR remission criteria: rationale for developing new criteria for remission.
Rheumatology (Oxford). 2012 Dec; 51 Suppl 6:vi16-20.R

Abstract

As more effective treatments for RA have become available, studies have demonstrated that in patients who attained remission, defined as a simplified disease activity index (SDAI) ≤3.3, not only disease activity but radiographic progression was reduced. The feasibility and the benefit of attaining remission led to the development of the ACR/European League Against Rheumatism (EULAR) 2011 remission criteria. These criteria employ either a Boolean definition, including tender and swollen joint counts ≤1, and CRP ≤1 mg/dl, or an index-based definition, SDAI ≤3.3, in combination with patient-reported outcomes on a scale of 0-10. It is expected that the ACR/EULAR criteria will be used as secondary outcomes in clinical trials. Some questions about the implementation of the new criteria include the availability of CRP values, and the possibility that patient-reported outcomes may skew the outcome if patients cannot distinguish other musculoskeletal conditions from RA. Several issues require further study, including the role of imaging, fatigue and the impact of the involvement of joints other than the 28 counted in the ACR/EULAR criteria.

Authors+Show Affiliations

Inflammatory Arthritis Center, Hospital for Special Surgery, 535 East 70th Street, 6th Floor, New York, NY 10021, USA. bykerkv@hss.eduNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

23221582

Citation

Bykerk, Vivian P., and Elena M. Massarotti. "The New ACR/EULAR Remission Criteria: Rationale for Developing New Criteria for Remission." Rheumatology (Oxford, England), vol. 51 Suppl 6, 2012, pp. vi16-20.
Bykerk VP, Massarotti EM. The new ACR/EULAR remission criteria: rationale for developing new criteria for remission. Rheumatology (Oxford). 2012;51 Suppl 6:vi16-20.
Bykerk, V. P., & Massarotti, E. M. (2012). The new ACR/EULAR remission criteria: rationale for developing new criteria for remission. Rheumatology (Oxford, England), 51 Suppl 6, vi16-20. https://doi.org/10.1093/rheumatology/kes281
Bykerk VP, Massarotti EM. The New ACR/EULAR Remission Criteria: Rationale for Developing New Criteria for Remission. Rheumatology (Oxford). 2012;51 Suppl 6:vi16-20. PubMed PMID: 23221582.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The new ACR/EULAR remission criteria: rationale for developing new criteria for remission. AU - Bykerk,Vivian P, AU - Massarotti,Elena M, PY - 2012/12/11/entrez PY - 2012/12/19/pubmed PY - 2013/4/3/medline SP - vi16 EP - 20 JF - Rheumatology (Oxford, England) JO - Rheumatology (Oxford) VL - 51 Suppl 6 N2 - As more effective treatments for RA have become available, studies have demonstrated that in patients who attained remission, defined as a simplified disease activity index (SDAI) ≤3.3, not only disease activity but radiographic progression was reduced. The feasibility and the benefit of attaining remission led to the development of the ACR/European League Against Rheumatism (EULAR) 2011 remission criteria. These criteria employ either a Boolean definition, including tender and swollen joint counts ≤1, and CRP ≤1 mg/dl, or an index-based definition, SDAI ≤3.3, in combination with patient-reported outcomes on a scale of 0-10. It is expected that the ACR/EULAR criteria will be used as secondary outcomes in clinical trials. Some questions about the implementation of the new criteria include the availability of CRP values, and the possibility that patient-reported outcomes may skew the outcome if patients cannot distinguish other musculoskeletal conditions from RA. Several issues require further study, including the role of imaging, fatigue and the impact of the involvement of joints other than the 28 counted in the ACR/EULAR criteria. SN - 1462-0332 UR - https://www.unboundmedicine.com/medline/citation/23221582/The_new_ACR/EULAR_remission_criteria:_rationale_for_developing_new_criteria_for_remission_ L2 - https://academic.oup.com/rheumatology/article-lookup/doi/10.1093/rheumatology/kes281 DB - PRIME DP - Unbound Medicine ER -